Technology
Health
Biotechnology

Co-Diagnostics

$0.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.1255 (-12.67%) Today
+$0.0352 (4.07%) After Hours

Why Robinhood?

You can buy or sell Co-Diagnostics and other stocks, options, ETFs, and crypto commission-free!

About

Co-Diagnostics, Inc. Common Stock, also called Co-Diagnostics, is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. Read More The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Employees
20
Headquarters
Salt Lake City, Utah
Founded
2013
Market Cap
12.80M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
548.77K
High Today
$0.9875
Low Today
$0.80
Open Price
$0.9875
Volume
399.06K
52 Week High
$6.66
52 Week Low
$0.80

Collections

Technology
Health
Biotechnology
Advertising and Marketing
Business Services
2017 IPO
US
North America

News

Yahoo FinanceMay 13

CEO Today Magazine Features Exclusive Interview with Co-Diagnostics Inc CEO Dwight Egan

New York City, May 13, 2019 (GLOBE NEWSWIRE) -- CEO Today Magazine Features Exclusive Interview with Co-Diagnostics Inc CEO Dwight Egan New York City, New York – The May 2019 issue of the prestigious CEO Today Magazine will include an interview with the CEO of Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, and client of BDA International. The interview provides details on a variety of subjects, including a lay...

152
Yahoo FinanceApr 30

Co-Diagnostics, Inc. Files Provisional Patent for Simplified Targeted NGS Library Preparation

SALT LAKE CITY--(BUSINESS WIRE)-- Method includes proprietary, single-step closed-tube NGS library prep in 3 hours or less Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced today the filing of a provisional patent with the USPTO for its single-step next generation sequencing (NGS) library preparation methods and composition, claiming an exclusive privilege and/or right to practice the invention, ...

167
NasdaqApr 25

Diagnostics Manufacturing Facility Launches in India to Service Growing Indian Healthcare Market

New York City, April 25, 2019 (GLOBE NEWSWIRE) -- The long-awaited molecular diagnostics manufacturing facility for the Indian joint venture between Co-Diagnostics Inc. and Synbiotics Pvt Ltd has finally launched, according to news released last week. BDA International client company Co-Diagnostics first announced the formation of the CoSara Diagnostics Pvt Ltd joint venture with Synbiotics in 2017. Since that time, shareholders have been eager for any news or updates concerning the completion of ...

95

Earnings

-$0.33
-$0.25
-$0.16
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.08 per share
Actual
-$0.09 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.